alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2014078EN.01001402.xml

| 15.3.2014 | EN | Official Journal of the European Union | C 78/14 |
| --- | --- | --- | --- |

15.3.2014

EN

Official Journal of the European Union

C 78/14

---

Action brought on 20 January 2014 — Sales & Solutions v OHIM — Wattline (WATTLINE)

(Case T-46/14)

2014/C 78/29

Language in which the application was lodged: German

Parties

Parties

Applicant: Sales & Solutions GmbH (Frankfurt am Main, Germany) (represented by: K. Gründig-Schnelle, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Other party to the proceedings before the Board of Appeal: Wattline GmbH (Ruderting, Germany)

Other party to the proceedings before the Board of Appeal:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | Alter the contested decision of the Fourth Board of Appeal of OHIM of 18 November 2013 in Case R 1668/2012-4 to the effect that the opposition is upheld in its entirety and the application for the Community trade mark is rejected; |
| --- | --- |

—

Alter the contested decision of the Fourth Board of Appeal of OHIM of 18 November 2013 in Case R 1668/2012-4 to the effect that the opposition is upheld in its entirety and the application for the Community trade mark is rejected;

| — | Order the intervener to pay the costs including those incurred in the course of the appeal proceedings. |
| --- | --- |

—

Order the intervener to pay the costs including those incurred in the course of the appeal proceedings.

Pleas in law and main arguments

Pleas in law and main arguments

Applicant for a Community trade mark: Wattline GmbH

Applicant for a Community trade mark:

Community trade mark concerned: the word mark ‘WATTLINE’ for services in Classes 35, 36 and 42 — Community trade mark application No 8 908 345

Community trade mark concerned:

Proprietor of the mark or sign cited in the opposition proceedings: the applicant

Proprietor of the mark or sign cited in the opposition proceedings:

Mark or sign cited in opposition: the German word and figurative mark and the Community word and figurative mark ‘Watt’ for services in Classes 35, 39 and 42

Mark or sign cited in opposition:

Decision of the Opposition Division: the opposition was upheld in part

Decision of the Opposition Division:

Decision of the Board of Appeal: the contested decision was annulled and the opposition was rejected

Decision of the Board of Appeal:

Pleas in law: Infringement of Article 8(1)(b) and (4) of Regulation (EC) No 207/2009 and infringement of Rule 20(7)(c) and Rule 50 of Commission Regulation (EC) No 2868/95

Pleas in law:

---
<Page>

INDEPENDENT AUDITORS' CONSENT

We consent to the use in this Post Effective Amendment No. 6 to Registration
Statement No. 333-95785 of Hartford Life and Annuity Insurance Company
Separate Account Seven of our report dated March 26, 2003, relating to the
financial statements of Hartford Life and Annuity Insurance Company, and of
our report dated February 21, 2003, relating to the financial statements of
Hartford Life and Annuity Insurance Company Separate Account Seven, appearing
in the Statement of Additional Information, which is a part of such
Registration Statement, and to the reference to us under the heading
"Independent Public Accountants" in such Statement of Additional Information.

Deloitte & Touche LLP

Hartford, Connecticut

April 7, 2003
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
balance sheets and statements of operations found on page 2 and 4 of the
Company's Form 10-Q for the year to date, and is qualified in its entirety by
reference to such financial statements.
</LEGEND>
<PERIOD-TYPE>                             6-MOS
<FISCAL-YEAR-END>                   DEC-31-1998
<PERIOD-END>                        JUN-30-1999
<CASH>                                2,673,907
<SECURITIES>                            197,947
<RECEIVABLES>                         1,174,565
<ALLOWANCES>                                  0
<INVENTORY>                           1,109,764
<CURRENT-ASSETS>                      5,801,403
<PP&E>                                4,609,344
<DEPRECIATION>                                0
<TOTAL-ASSETS>                       10,904,185
<CURRENT-LIABILITIES>                   523,967
<BONDS>                                       0
<COMMON>                              9,760,214
<PREFERRED-MANDATORY>                         0
<PREFERRED>                                   0
<OTHER-SE>                              179,948
<TOTAL-LIABILITY-AND-EQUITY>         10,904,185
<SALES>                               5,503,329
<TOTAL-REVENUES>                      5,503,329
<CGS>                                 3,447,104
<TOTAL-COSTS>                         3,447,104
<OTHER-EXPENSES>                      1,871,812
<LOSS-PROVISION>                              0
<INTEREST-EXPENSE>                            0
<INCOME-PRETAX>                         253,551
<INCOME-TAX>                            101,420
<INCOME-CONTINUING>                     152,131
<DISCONTINUED>                                0
<EXTRAORDINARY>                               0
<CHANGES>                                     0
<NET-INCOME>                            152,131
<EPS-BASIC>                               .08
<EPS-DILUTED>                               .08

</TABLE>
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.2260 High pressure liquid chromatography system for clinical use. ( a ) *Identification.* A high pressure liquid chromatography system for clinical use is a device intended to separate one or more drugs or compounds from a solution by processing the mixture of compounds (solutes) through a column packed with materials of uniform size (stationary phase) under the influence of a high pressure liquid (mobile phase). Separation of the solutes occurs either by absorption, sieving, partition, or selective affinity.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2309, Jan. 14, 2000]
**Exhibit 31.2**

**CERTIFICATION**

I, Carl Serger, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Ebix, Inc.;

2. Based on my knowledge, this report does not contain any untruestatement of a material fact or omit to state a material fact necessary to makethe statements made, in light of the circumstances under which such statementswere made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financialinformation included in this report, fairly present in all material respectsthe financial condition, results of operations and cash flows of the registrantas of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible forestablishing and maintaining disclosure controls and procedures (as defined inExchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused suchdisclosure controls and procedures to be designed under our supervision, toensure that material information relating to the registrant, including itsconsolidated subsidiaries, is made known to us by others within those entities,particularly during the period in which this report is being prepared;

(b) Evaluated the effectiveness of the registrant’s disclosure controlsand procedures and presented in this report our conclusions about theeffectiveness of the disclosure controls and procedures, as of the end of theperiod covered by this report based on such evaluation; and

(c) Disclosed in this report any change in the registrant’s internalcontrol over financial reporting that occurred during the registrant’s mostrecent fiscal quarter (the registrant’s fourth fiscal quarter in the case of anannual report) that has materially affected, or is reasonably likely tomaterially affect, the registrant’s internal control over financial reporting;and

5. The registrant’s other certifying officer and I have disclosed,based on our most recent evaluation of internal control over financialreporting, to the registrant’s auditors and the audit committee of theregistrant’s board of directors (or persons performing the equivalentfunctions):

(a) All significant deficiencies and material weaknesses in the designor operation of internal control over financial reporting which are reasonablylikely to adversely affect the registrant’s ability to record, process,summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management orother employees who have a significant role in the registrant’s internalcontrol over financial reporting.

 
| Date: May 21, 2007 | /s/ Carl A.Serger       |   |
|--------------------|-------------------------|--------|
|               | Carl A. Serger          |   |
|               | Chief Financial Officer |   |

 

 

----
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         Center for Scientific Review Special Emphasis Panel; Member Conflict: Cellular and Developmental Neuroscience.                    

*Date:*                         March 24, 2010.                    

*Time:*                         1 p.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Telephone Conference Call).                    

*Contact Person:*                         Deborah L. Lewis, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4183, MSC 7850, Bethesda, MD 20892, 301-408-9129,                         *lewisdeb@csr.nih.gov.*

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: March 2, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-5018 Filed 3-9-10; 8:45 am]

BILLING CODE 4140-01-P
[Federal Register Volume 75, Number 43 (Friday, March 5, 2010)]
[Notices]
[Page 10296]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4749]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel, Topics in Epidemiology.
    Date: March 31-April 1, 2010.
    Time: 8:30 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892, (Virtual Meeting).
    Contact Person: Suzanne Ryan, PhD, Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 3139, Bethesda, MD 20892, (301) 435-1712, 
<a href="/cdn-cgi/l/email-protection#a7d5dec6c9d4cde7c4d4d589c9cecf89c0c8d1"><span class="__cf_email__" data-cfemail="d4a6adb5baa7be94b7a7a6fababdbcfab3bba2">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: March 1, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-4749 Filed 3-4-10; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
<PAGE>   1

                                                                   EXHIBIT 11.1

                            A-FEM MEDICAL CORPORATION
                       CALCULATIONS OF NET LOSS PER SHARE

<TABLE>
<CAPTION>

                                          FOR THE THREE MONTHS                FOR THE SIX MONTHS
                                             ENDED JUNE 30                          JUNE 30,
                                       -----------------------------      ----------------------------------
                                            1999           1998                 1999               1998
                                       ------------    -------------      ---------------    ---------------
<S>                                       <C>            <C>                  <C>              <C>
Actual weighted average
shares outstanding                        9,498,249       13,698,454            9,485,135         13,596,713

Dilutive common stock, options
  and warrants using the
  treasury stock method(1)                       --               --                   --                 --
                                       ------------    -------------      ---------------    ---------------

Total shares used in per
  share calculations                      9,498,249       13,698,454            9,485,135         13,596,713

Net loss                               $   (653,246)     $  (910,285)       $  (1,349,361)     $  (2,119,492)

Net loss per share                     $      (0.07)     $     (0.07)       $       (0.14)     $       (0.16)
</TABLE>

(1)  Preferred stock, warrants and options outstanding are not included, as the
     effect would be anti-dilutive.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         Heart, Lung, and Blood Initial Review Group; Heart, Lung, and Blood Program Project Review Committee.                    

*Date:*                         March 19, 2010.                    

*Time:*                         8 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.                    

*Contact Person:*                         Jeffrey H. Hurst, PhD, Scientific Review Officer, Review Branch/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7208, Bethesda, MD 20892-7924, 301-435-0303,                         *hurstj@nhlbi.nih.gov*.                    

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: February 23, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-4493 Filed 3-3-10; 8:45 am]

BILLING CODE 4140-01-P
## S IXTH 

## D ISTRICT 

## C OURT OF 

## A PPEAL 

## S TATE OF 

## F LORIDA

_____________________________ Case No. 6D2 3

- 309 Lower Tribunal No. CF 20

- 00 3695

- XX

_____________________________ R OBERTO L. R ODRIGUEZ , Appellant
,

v.
S TATE OF F LORIDA , Appellee

.

_____________________________ Appeal from the Circuit Court for Polk County

.

J. Kevin Abdoney , Judge.
February 13, 2024

PER CURIAM

.
AFFIRMED

.
WHITE , BROWNLEE and GANNAM , JJ., c oncur.

Howard L. “Rex” Dimmig, II, Public Defender, and Richard J. Sanders, Assistant Public Defender, Bartow
, for Appellant

.
Roberto L. Rodriguez, Crawfordville, pro se

. Ashley Moody, Attorney General, Tallahassee, and Helene S. Parnes, Senior Assistant Attorney General, Tampa, for Appellee.

NOT FINAL UNTIL TIM E EXPIRES TO FILE MOTION FOR REHEARING AND

DISPOSITION THEREOF IF TIMELY FILED
Editorial Note on Part 874
Editorial Note: Nomenclature changes to part 874 appear at 73 FR 35341, June 23, 2008.

§ 874.3315 Tympanic membrane contact hearing aid. ( a ) *Identification.* A tympanic membrane contact hearing aid is a prescription wearable device that compensates for impaired hearing. Amplified sound is transmitted by vibrating the tympanic membrane through a transducer that is in direct contact with the tympanic membrane. A tympanic membrane contact hearing aid is subject to the requirements in § 801.422 of this chapter.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) The patient contacting components must be demonstrated to be biocompatible.
( 2 ) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use, and must include: ( i ) Mechanical integrity testing;
( ii ) Electrical and thermal safety testing;
( iii ) Software verification, validation, and hazard analysis;
( iv ) Reliability testing consistent with expected device life;
( v ) Electromagnetic compatibility testing; and
( vi ) Validation testing of device output and mechanical force applied to the tympanic membrane in a clinically appropriate model.
( 3 ) Clinical performance testing must characterize any adverse events observed during clinical use, and demonstrate that the device performs as intended under anticipated conditions of use.
( 4 ) Professional training must include the ear impression procedure, correct placement, fitting, monitoring, care, and maintenance of the device.
( 5 ) Labeling must include the following: ( i ) A detailed summary of the adverse events and effectiveness outcomes from the clinical performance testing;
( ii ) Detailed instructions on how to fit the device to the patient;
( iii ) Instructions for periodic cleaning of any reusable components;
( iv ) Information related to electromagnetic compatibility; and
( v ) Patient labeling that includes: ( A ) A patient card that identifies if a patient has been fitted with any non-self- removable components of the device and provides relevant information in cases of emergency;
( B ) Information on how to correctly use and maintain the device;
( C ) The potential risks and benefits associated with the use of the device; and
( D ) Alternative treatments.
[81 FR 3326, Jan. 21, 2015, as amended at 87 FR 50762, Aug. 17, 2022]
WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.

<TABLE> <S> <C>

<PERIOD  TYPE>     3-MOS
<FISCAL-YEAR-END>              MAR-31-2000
<PERIOD-END>                   DEC  31-1999
<CASH>                         43,000
<SECURITIES>                   0
<RECEIVABLES>                  1,597,000
<ALLOWANCES>                   (217,000)
<INVENTORY>                    1,193,000
<CURRENT-ASSETS>               2,677,000
<PP&E>                         2,797,000
<DEPRECIATION>                 (961,000)
<TOTAL-ASSETS>                 6,872,000
<CURRENT-LIABILITIES>          4,886,000
<BONDS>                        0
<PREFERRED-MANDATORY>          0
<PREFERRED>                    0
<COMMON>                       21,413,000
<OTHER-SE>                     69,000
<TOTAL-LIABILITY-AND-EQUITY>   6,872,000
<SALES>                        2,105,000
<TOTAL-REVENUES>               2,105,000
<CGS>                          1,405,000
<TOTAL-COSTS>                  1,405,000
<OTHER-EXPENSES>               1,313,000
<LOSS-PROVISION>               0
<INTEREST-EXPENSE>             40,000
<INCOME-PRETAX>                (433,000)
<INCOME-TAX>                   0
<INCOME-CONTINUING>            (433,000)
<DISCONTINUED>                 0
<EXTRAORDINARY>                0
<CHANGES>                      0
<NET-INCOME>                   (433,000)
<EPS-BASIC>                  (0.04)
<EPS-DILUTED>                  (0.04)



</TABLE>